Ovid Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ovid Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2016 to Q3 2024.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.31M, a 19.8% decline year-over-year.
  • Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $6.81M, a 5.79% decline year-over-year.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.29M, a 11.1% increase from 2022.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.56M, a 29.7% increase from 2021.
  • Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5.05M, a 32.8% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.81M $1.31M -$323K -19.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $7.13M $1.74M -$208K -10.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $7.34M $1.97M +$52K +2.71% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $7.29M $1.79M +$60.6K +3.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-08
Q3 2023 $7.22M $1.63M -$151K -8.48% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $7.38M $1.95M +$228K +13.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $7.15M $1.92M +$591K +44.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $6.56M $1.73M +$414K +31.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 $6.14M $1.78M +$620K +53.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $5.52M $1.72M +$463K +36.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 $5.06M $1.32M +$4.81K +0.36% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $5.05M $1.32M -$736K -35.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-13
Q3 2021 $5.79M $1.16M -$1.45M -55.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $7.24M $1.26M -$298K -19.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $7.54M $1.32M +$17.1K +1.31% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $7.53M $2.05M +$924K +82% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 $6.6M $2.62M +$1.43M +121% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $5.17M $1.56M +$303K +24.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $4.87M $1.3M -$340K -20.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $5.21M $1.13M -$604K -34.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-15
Q3 2019 $5.81M $1.18M -$509K -30.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $6.32M $1.25M -$592K -32.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $6.91M $1.64M -$152K -8.49% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $7.06M $1.73M +$320K +22.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $6.74M $1.69M +$318K +23.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $6.43M $1.84M -$349K -15.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $6.77M $1.79M +$376K +26.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $6.4M $1.41M +$362K +34.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 $6.04M $1.38M +$280K +25.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $5.76M $2.19M +$1.42M +182% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $4.34M $1.42M +$698K +96.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $3.64M $1.05M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-29
Q3 2016 $1.1M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $777K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $721K Jan 1, 2016 Mar 31, 2016 10-Q 2017-06-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.